Abstract
Lutetium-177 prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an option for treatment of metastatic castration-resistant prostate cancer (mCRPC). It is increasingly used in old or comorbid patients. Purpose was to evaluate the safety and efficacy in patients ≥80 years of age.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
